Treatment of pulmonary hypertension with carbonic anhydrase inhibitors

Inventors

Najarian, Thomas • Tam, Peter Y. • Wilson, Leland F. • Peterson, Craig

Assignees

Vivus LLC

Interested in licensing this patent?

MTEC can help explore whether this patent might be available for licensing for your application.

Publication Number

US-8071557-B2

Patent

Publication Date

2011-12-06

Expiration Date


Abstract

This disclosure relates generally to methods and pharmaceutical compositions useful in treating pulmonary hypertension. In one embodiment, for example, the disclosure provides a method for treating pulmonary hypertension comprising administering a therapeutically effective dose of a carbonic anhydrase inhibitor to a patient in need of treatment. The disclosure finds utility in the fields of medicine and pharmacology.

Core Innovation

The supplied patent content describes treatment of pulmonary hypertension with carbonic anhydrase inhibitors, particularly topiramate, used alone or with additional agents. The independent claims focus on topiramate administered with a Type V phosphodiesterase inhibitor for primary pulmonary hypertension, and on a regimen in which topiramate is gradually increased to a maintenance dose while the inhibitor is administered.

The content also describes controlled-release formulations and treatment of associated conditions. Patient examples report improved symptoms and reduced or normalized pulmonary pressures during topiramate-containing regimens, although weight-loss measures are also reported as part of the treatment. The background section is not included in the supplied content, so the problem identified there is not explicitly described.

Claims Coverage

The claim coverage encompasses two inventive features directed to treating primary pulmonary hypertension.

Combination treatment for primary pulmonary hypertension

Independent claim 1 covers administering therapeutically effective doses of topiramate and a Type V phosphodiesterase inhibitor to treat primary pulmonary hypertension. Dependent claims identify inhibitor options, including avanafil, sildenafil, and tadalafil, and specify dosage-form and release characteristics.

Gradual increase of the topiramate dose

Independent claim 22 covers treating primary pulmonary hypertension with topiramate administered at a daily dose that is gradually increased from an initial dosage to a final dosage suitable for continued maintenance therapy, together with a Type V phosphodiesterase inhibitor.

The claims cover two treatment approaches for primary pulmonary hypertension: combination administration of topiramate with a Type V phosphodiesterase inhibitor, and that combination with gradual escalation of the topiramate dose to maintenance therapy.

Stated Advantages

Not explicitly described in patent.

Documented Applications

Treatment of primary pulmonary hypertension using topiramate with a Type V phosphodiesterase inhibitor, including a regimen with gradual topiramate dose escalation.

A dependent claim identifies congestive heart failure as an additional physiological condition treated by the inhibitor.

JOIN OUR MAILING LIST

Stay Connected with MTEC

Keep up with active and upcoming solicitations, MTEC news and other valuable information.